

hu



Huons Global

4Q 2023 Business Performance

2024. 02. 14.



Huons Global

Disclaimer

All information in this book including business performance and financial report is written by Korean-International Financial Reporting Standards(K-IFRS) .

This book includes a “forecast” about future. It is not about the past, but the future business plan including expected management status and financial performance, and sometimes there can be word such as ‘anticipation’, ‘forecast’, ‘plan’, ‘expectation’, and ‘(E)’.

A “forecast” can mean uncertain factors which can affect the company either positively or vice versa, and those can include:

- Domestic or international financial market trends including fluctuation of foreign exchange rate or interest rate.
- Company’s very important strategic decision such as M&A
- Unexpected business environment change in the main industry
- Other internal and external change that can affect the company’s management and finance.

Because of those uncertain risks, company’s actual business performance can be different from the “forecast” in this booklet. Also the information we provide is written as of the day we deliver the presentation, so it can be changed due to unexpected external status of industry or internal company’s revision of strategies without any prior notice in the future.


Contents

- 1. Business Performance**
- 2. Subsidiaries : Profit&Loss Status**
- 3. Huons Group Affiliates**
- 4. Shareholder Return Policy**
- 5. Appendix**

- Reached peak sales by continuing high-growth in overall business


Sales

[Unit : billion KRW]




Operating Profit

[Unit : billion KRW]



Net Profit

[Unit : billion KRW]



[Sales]

- 200.1 bil KRW** (YoY ▲15.6%, QoQ ▲5.0%)
- ✓ Continuous high-growth in ETC division
 - ✓ Increasing demand for esthetics(filler, BTX)

[Operating Profit]

21.9 bil KRW (YoY ▼18.7%, QoQ ▼31.3%)


[Net Profit]

- 16.3 bil KRW** (YoY Turn to profit, QoQ ▼30.2%)
- ✓ One-time cost incurred (personal expense, marketing)
 - ✓ Major subsidiary's cost ratio rose
 - Maintenance of facilities,
 - Provision for inventory assets

- Even growth of all subsidiaries → highest annual performance


Sales

[Unit : billion KRW]




Operating Profit

[Unit : billion KRW]



Net Profit

[Unit : billion KRW]



[Sales]

758.4 bil KRW (YoY ▲14.2%)

[Operating Profit]

114.8 bil KRW (YoY ▲32.8%)

- ✓ Increased exports (filler, BTX)
- ✓ Growth in high-yield major business(ETC, esthetic, BTX)

[Net Profit]

85.3 bil KRW (YoY Turn to profit)

- ✓ Base effect of damaged losses on intangible assets(Subsidiary goodwill, etc.)

hu Huons Global 2. Subsidiaries_Profit&Loss Status_4Q23

(Unit : Million KRW)

Classification	Sales					Operating Profit					Net Profit				
	4Q23	4Q22	3Q23	YoY	QoQ	4Q23	4Q22	3Q23	YoY	QoQ	4Q23	4Q22	3Q23	YoY	QoQ
Huons Global (Consolidated)	200,055	173,097	190,617	+15.6%	+5.0%	21,903	26,955	31,901	-18.7%	-31.3%	16,332	-72,189	23,387	Turn to Profit	-30.2%
Huons Global (Separated)	8,068	8,276	10,532	-2.5%	-23.4%	618	2,721	4,267	-77.3%	-85.5%	6,106	-8,770	3,881	Turn to Profit	+57.3%
Huons	145,224	129,314	138,166	+12.3%	+5.1%	10,978	16,240	14,952	-32.4%	-26.6%	9,198	3,764	11,780	+144.4%	-21.9%
Humedix	36,736	32,684	39,655	+12.4%	-7.4%	5,257	6,265	11,355	-16.1%	-53.7%	4,906	-1,868	7,215	Turn to Profit	-32.0%
HuM&C (Consolidated)	11,312	10,706	12,563	+5.7%	-10.0%	1,036	486	1,543	+113.2%	-32.9%	1,366	-626	1,143	Turn to Profit	+19.5%
Huons Meditech	15,992	15,472	13,643	+3.4%	+17.2%	1,752	2,679	601	-34.6%	+191.6%	1,731	2,005	204	-13.7%	+750.0%
Huons Biopharma	11,517	11,996	9,219	-4.0%	+24.9%	4,080	2,209	2,547	+84.7%	+60.2%	6,467	2,174	2,801	+197.4%	+130.9%
Huons Lab	-	-	-	-	-	-2,430	-626	-1,887	-	-	-2,029	-1,091	-1,932	-	-
Huons USA	446	99	282	+350.0%	+57.9%	151	-145	12	Turn to Profit	+1,194.3%	146	779	2	-81.3%	+7,741.9%
Huons JAPAN	125	75	99	+67.5%	+27.1%	39	-35	6	Turn to Profit	+575.2%	27	-35	6	Turn to Profit	+371.3%

* HuM&C applied consolidated criteria due to incorporated subsidiary(HuM&C Vina)


Huons Global 2. Subsidiaries_Profit&Loss Status_Yearly

(Unit : Million KRW)

구분	Sales				Operating Profit				Net Profit			
	2021	2022	2023	YoY	2021	2022	2023	YoY	2021	2022	2023	YoY
Huons Global (Consolidated)	574,648	664,365	758,380	+14.2%	74,302	86,476	114,814	+32.8%	32,071	-33,463	85,281	Turn to Profit
Huons Global (Separated)	32,194	32,931	39,328	+19.4%	8,311	11,090	11,066	-0.2%	52,305	4,175	12,337	+195.5%
Huons	436,911	492,387	552,007	+12.1%	45,282	40,867	54,993	+34.6%	30,581	22,608	49,709	+119.9%
Humedix	110,992	123,173	152,274	+23.6%	15,990	26,043	37,310	+43.3%	10,051	21,154	26,482	+25.2%
HuM&C (Consolidated)	12,543	35,630	48,425	+35.9%	-1,929	1,766	4,842	+174.1%	-6,178	798	7,844	+882.6%
Huons Meditech	41,058	62,075	59,479	-4.2%	5,984	9,796	5,216	-46.8%	4,733	7,821	5,421	-30.7%
Huons Biopharma	15,155	31,596	44,265	+40.1%	2,803	6,183	14,869	+140.5%	2,503	6,136	17,773	+189.6%
Huons Lab	192	87	-	-100.0%	-2,800	-3,692	-6,313	-	-3,017	-4,260	-6,050	-
Huons USA	76	99	1,085	+994.9%	-3,575	-4,933	147	Turn to Profit	-3,425	-3,183	-1,699	-
Huons JAPAN	-	75	477	+537.9%	-	-242	63	Turn to Profit	-	-242	51	Turn to Profit

* HuM&C became Consolidated due to incorporating subsidiary(HuM&C Vina)

“Total Healthcare Group”
Includes Pharma, Medical Device, Health Functional Food and Cosmetic business



※ Percentage of shares is based on total number of issued shares including preferred shares.

• **New Affiliates**

- Food Assemble (New business in ready-made food)
- Crystal Life Science (Increasing the productivity of pharmaceuticals)
- HuM&C VINA (Medical containers manufacture plant located overseas)

Toal 1,800 people

Company share ratio

KOSDAQ Listed

Strengthened shareholder return policy – Raised DPS & Interim Dividend Introduction

- Transparent and active shareholder return policy for enhancement of corporate value
- Implementation of Interim Dividend : Twice a year(Interim&Year-end)

- Operation of long-term dividend policy : Rasing DPS Yearly by 0~30%
→ Increased by 5% in 2023


[FY 2023 Cash Dividends]

Dividend Type	Interim	Year-end
Dividend per Share	250 KRW	275 KRW
	Yearly : 525 KRW (FY2022 : 500 KRW)	
Dividend Ratio to Market Value ¹⁾	1.19%	1.15%
Total Dividend Amount	3,062,018,750 KRW	3,368,220,625 KRW
Dividend Record Date	2023-06-30	2024-04-01
Scheduled Dividend Payment Date	2023-08-25	2024-04-19

* Dividends will be finally approved by the general shareholders' meeting

1) Calculated by the dividend percentage per share based on the average arithmetic price of the final price formed in the securities market during the previous week, starting from a day before the date of resolutions.

[Total Annual Dividends]



Consolidated Statement of Financial Position

[Unit: million KRW]

Classification	4Q22	1Q23	2Q23	3Q23	4Q23
Assets	1,243,109	1,223,154	1,242,941	1,272,494	1,321,320
Current assets	611,226	585,663	586,850	605,141	590,466
Cash etc.*	364,473	323,646	306,963	318,183	304,990
Accounts receivable	107,142	114,355	124,504	124,383	138,219
Non-current assets	631,883	637,491	656,091	667,353	730,855
Liabilities	457,234	418,098	393,660	393,601	418,000
Current liabilities	367,562	333,087	306,249	303,752	306,393
Short-term borrowings	107,461	107,699	100,990	100,404	122,657
Current portion of long-term debt	-	6,033	6,033	21,033	31,273
Non-current liabilities	89,671	85,011	87,411	89,849	111,607
Long-term borrowings	70,826	65,000	65,000	65,000	66,943
Equity	785,876	805,056	849,281	878,894	903,320
Equity attributable to owners of parent	464,316	466,792	478,746	489,499	495,665
Retained earnings	116,845	117,427	125,298	133,299	139,799
Non-controlling interests	321,559	338,264	370,534	389,395	407,655
Stability Indicator					
Current ratio	166.3%	175.8%	191.6%	199.2%	192.7%
Debt to equity ratio	58.2%	51.9%	46.4%	44.8%	46.3%
Borrowing ratio	22.7%	22.2%	20.3%	21.2%	24.5%
Interest coverage ratio	697%	665%	1,259%	1,126%	839%

* Cash etc. = Cash & Cash Equivalent + Short-term Financial Instruments

** Figures accumulated for 4 quarters

Financial Statements of Comprehensive Income

[Unit: million KRW]

Classification	4Q22	1Q23	2Q23	3Q23	4Q23
Sales	173,097	173,964	193,744	190,617	200,055
SG&A expenses	146,142	149,503	157,196	158,715	178,151
Operating Profit	26,955	24,460	36,549	31,901	21,903
Gains on valuation using equity method	(420)	306	(166)	152	(328)
Other revenues	(739)	2,257	3,801	1,670	1,793
Other expense	80,356	2,258	1,463	916	1,085
Interest expense	3,870	3,678	2,903	2,833	2,611
Profit before tax	(55,630)	33,357	31,101	32,671	24,964
Income tax expense	15,760	10,597	8,299	9,284	8,632
Net Profit	(72,189)	22,760	22,802	23,387	16,332
Profit, attributable to owners	(74,266)	6,706	7,871	11,063	6,504
Profit, attributable to non-controlling interests	2,077	16,054	14,932	12,324	9,828
Profitability Indicator					
Operating profit ratio	15.6%	14.1%	18.9%	16.7%	10.9%
EBITDA Margin	20.6%	19.0%	23.3%	21.5%	10.9%
Net profit ratio	-41.7%	13.1%	11.8%	12.3%	8.2%
ROE**	52.6%	54.1%	55.8%	56.9%	59.1%
Sales/Asset**	158.2%	151.9%	146.4%	144.8%	146.3%

Thank you